February 2025

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online 
NIPGR looking for Project Scientist
16 February 2025

NIPGR looking for Project Scientist - Salary Rs. 56000 plus HRA pm

Candidates having M.Tech Engineering or Technology or Ph.D degree awarded in Life Sciences, Biotechnology, Plant Molecular Biology or any other related field and fulfilling the guidelines, norms of DST Office Memorandum dated July 10, 2020 are eligible to apply. The candidate should have research experience in Bioinformatics.
16 February 2025
Advertisement for M.Pharm, MSc, MTech under Research Project at Tata Medical Center
NEO - HYPORT, Does Neoadjuvant radiotherapy NART improve breast cancer outcomes. Tata Medical Center, Kolkata, is a state-of-the-art tertiary Comprehensive Cancer Care Center being established to serve the needs of society in the eastern part of India.
15 February 2025
Opportunity for Pharmaceutical Sciences to Join NDTL as Scientist
Plan the new areas in the growing field of analytical testing in the field of Human Doping. Oversee the refinement of the existing analytical techniques as per WADA directions, from time to time, in respect of the specialties, sub- specialties handled by the NDTL.
15 February 2025
Pharma and Life Sciences Recruitment as Clinical Trial Coordinator at MPMMCC
Graduate in Life Science, B.Pharmacy with Diploma in Clinical Research. Relevant experience in clinical research.
15 February 2025
Interview for M.Pharm, B.Pharm, MSc in QC, IPQA, ADL at Concord Biotech

Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. Concord, founded in the year 2000 has transformed from a single-product company to a broad-spectrum solution provider, offering products across diversified therapeutic segments.

WALK IN INTERVIEW

15 February 2025
BMS melanoma drug failed in clinical trial
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag nivolumab and relatlimab-rmbw for the adjuvant treatment of patients with completely resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free survival.
15 February 2025
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Pfizer Inc announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA talazoparib, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI enzalutamide, an androgen receptor pathway inhibitor ARPI, demonstrating a statistically significant and clinically meaningful improvement in overall survival OS compared to placebo plus XTANDI in patients with metastatic castration-resistant prostate cancer mCRPC, with or without homologous recombination repair HRR gene mutations.
15 February 2025
Breakthrough in Click Chemistry : Innovative Method Revolutionizes Drug Development

Middle molecules with a molecular weight of more than 1,000 are difficult to synthesize due to multiple steps and time-consuming nature, demanding the development of a new approach that can overcome these disadvantages. Click chemistry has become an essential tool in applied chemistry due to its simplicity, efficiency, and versatility. This approach to chemical synthesis allows for quick and reliable joining of small molecules into larger, more complex structures, often with minimal side reactions and byproducts.

15 February 2025
New blood test identifies hard-to-detect pancreatic cancer with 85% accuracy
A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the deadliest cancers. Researchers at Oregon Health & Science University have developed a test called PAC-MANN, the abbreviation for protease activity-based assay using a magnetic nanosensor which uses a small blood sample to detect changes in protease activity a key indicator of pancreatic ductal adenocarcinoma, or PDAC, the most common and deadly form of pancreatic cancer.
15 February 2025
Diabetes Can Drive the Evolution of Antibiotic Resistance

Antibiotics are powerful, fast-acting medications designed to eradicate bacterial infections. However, in recent years, their dependability has waned as antibiotic resistant bacteria continues to evolve and spread.

Staphylococcus aureus is a leading cause of antibiotic resistance associated infections and deaths. It is also the most prevalent bacterial infection among those with diabetes mellitus, a chronic condition that affects blood sugar control and reduces the body’s ability to fight infections.